Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:2871 |
Name | endometrial carcinoma |
Definition | A endometrial cancer that is located_in the tissue lining the uterus. |
Source | DiseaseOntology.org |
Alt Ids | DOID:3000 |
Path | disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer female reproductive organ cancer uterine cancer endometrial cancer endometrial carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
FGFR2 N549K | FIIN-1 | endometrial carcinoma | sensitive | detail... |
FGFR2 K310R FGFR2 N549K | FIIN-1 | endometrial carcinoma | sensitive | detail... |
FGFR2 wild-type | FIIN-1 | endometrial carcinoma | resistant | detail... |
FGFR2 S252W | RO4987655 | endometrial carcinoma | decreased response | detail... |
FGFR2 N549K | RO4987655 | endometrial carcinoma | no benefit | detail... |
FGFR2 K310R FGFR2 N549K | RO4987655 | endometrial carcinoma | no benefit | detail... |
FGFR2 N549K | RO5126766 | endometrial carcinoma | no benefit | detail... |
FGFR2 K310R FGFR2 N549K | RO5126766 | endometrial carcinoma | no benefit | detail... |
FGFR2 S252W | Selumetinib | endometrial carcinoma | decreased response | detail... |
FGFR2 N549K | Selumetinib | endometrial carcinoma | no benefit | detail... |
FGFR2 K310R FGFR2 N549K | Selumetinib | endometrial carcinoma | no benefit | detail... |
FGFR2 S252W | RO5126766 | endometrial carcinoma | sensitive | detail... |
PIK3CA R88L PIK3CA E453del PIK3CA T1052K PTEN loss PTEN mut | Copanlisib | endometrial carcinoma | sensitive | detail... |
FGFR2 S252W | GSK3052230 | endometrial carcinoma | sensitive | detail... |
MLH1 mutant | N/A | endometrial carcinoma | not applicable | detail... |
MSH6 mutant | N/A | endometrial carcinoma | not applicable | detail... |
PIK3CA mutant | Copanlisib | endometrial carcinoma | no benefit | detail... |
TP53 mutant | Adavosertib | endometrial carcinoma | predicted - sensitive | detail... |
PTEN negative | Olaparib | endometrial carcinoma | no benefit | detail... |
PTEN negative | Buparlisib | endometrial carcinoma | sensitive | detail... |
PTEN negative | Buparlisib + Olaparib | endometrial carcinoma | sensitive | detail... |
PTEN del | Olaparib | endometrial carcinoma | no benefit | detail... |
PTEN del | Buparlisib | endometrial carcinoma | sensitive | detail... |
PTEN del | Buparlisib + Olaparib | endometrial carcinoma | sensitive | detail... |
MLH1 negative | Pembrolizumab | endometrial carcinoma | sensitive | detail... |
MSH6 negative | Pembrolizumab | endometrial carcinoma | sensitive | detail... |
MSH6 negative | Dostarlimab-gxly | endometrial carcinoma | sensitive | detail... |
MLH1 negative | Dostarlimab-gxly | endometrial carcinoma | sensitive | detail... |
MLH1 negative | Nivolumab | endometrial carcinoma | sensitive | detail... |
MSH6 negative | Nivolumab | endometrial carcinoma | sensitive | detail... |
MLH1 negative | Avelumab | endometrial carcinoma | sensitive | detail... |
MSH6 negative | Avelumab | endometrial carcinoma | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00492778 | Phase II | Cisplatin | Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer | Active, not recruiting | USA | CAN | 0 |
NCT00996892 | Phase I | Cobimetinib + Pictilisib | Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors | Terminated | USA | 0 |
NCT01174121 | Phase II | Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer | Recruiting | USA | 0 |
NCT01440998 | Phase I | Carboplatin + Dasatinib + Paclitaxel | Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer | Completed | USA | 0 |
NCT01504126 | Phase I | Propranolol | Beta-Blocker / Ovarian | Completed | USA | 0 |
NCT01888562 | Phase I | Ponatinib | Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma | Withdrawn | 0 | |
NCT01935973 | Phase II | Trametinib Trametinib + Uprosertib | Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer | Completed | USA | 0 |
NCT02059265 | Phase II | Dasatinib | Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer | Terminated | USA | 0 |
NCT02065687 | Phase III | Carboplatin + Metformin + Paclitaxel Carboplatin + Paclitaxel | Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer | Unknown status | USA | 0 |
NCT02117817 | Phase I | Buparlisib + Nab-paclitaxel | Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer | Withdrawn | 0 | |
NCT02228681 | Phase II | Tamoxifen Medroxyprogesterone Everolimus + Letrozole | Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer | Completed | USA | 0 |
NCT02397083 | Phase II | Everolimus | Phase II Study of Intrauterine Device (IUD) Alone or in Combination With Everolimus in Endometrial Cancer | Active, not recruiting | USA | 0 |
NCT02454972 | Phase II | Lurbinectedin | Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors | Completed | USA | SWE | ITA | GBR | FRA | ESP | DEU | CHE | BEL | 0 |
NCT02549209 | Phase II | Carboplatin + Paclitaxel + Pembrolizumab | Pembro/Carbo/Taxol in Endometrial Cancer | Completed | USA | 0 |
NCT02549989 | Phase II | LY3023414 | Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer | Completed | USA | 0 |
NCT02558348 | Phase Ib/II | Anlotinib | Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001) | Terminated | USA | 0 |
NCT02611024 | Phase Ib/II | Irinotecan + Lurbinectedin | Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors | Recruiting | USA | ITA | FRA | ESP | DEU | CHE | 0 |
NCT02628067 | Phase II | Pembrolizumab | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | Recruiting | USA | POL | NOR | NLD | ITA | ISR | FRA | ESP | DNK | DEU | BRA | AUS | 9 |
NCT02725268 | Phase II | Paclitaxel Sapanisertib Sapanisertib + Serabelisib | Phase 2 Study of MLN0128, Combination of MLN0128 With MLN1117, Paclitaxel and Combination of MLN0128 With Paclitaxel in Women With Endometrial Cancer | Completed | USA | NOR | NLD | ITA | GBR | ESP | DEU | CAN | BEL | AUS | 0 |
NCT02807844 | Phase Ib/II | MCS110 + Spartalizumab | Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | Completed | USA | ITA | FRA | FIN | ESP | DEU | CHE | BEL | 3 |
NCT02977195 | Phase I | NP137 | First in Human Evaluation of Safety, Pharmacokinetics, and Clinical Activity of a Monoclonal Antibody Targeting Netrin 1 in Patients With Advanced/Metastatic Solid Tumors (NP137) | Completed | FRA | 0 |
NCT03008408 | Phase II | Everolimus + Letrozole + Ribociclib | Phase II Ribociclib, Everolimus and Letrozole in Endometrial Cancer | Active, not recruiting | USA | 0 |
NCT03015129 | Phase II | Durvalumab Durvalumab + Tremelimumab | A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer | Completed | USA | 0 |
NCT03076372 | Phase I | MM-310 | A Study Evaluating MM-310 in Patients With Solid Tumors | Unknown status | USA | 0 |
NCT03077698 | Phase II | Megestrol acetate + Sodium cridanimod | An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer | Terminated | USA | 0 |
NCT03138408 | Phase I | SC-004 Budigalimab + SC-004 | SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancers | Terminated | USA | 0 |
NCT03192059 | Phase II | Aspirin + Cyclophosphamide + Pembrolizumab + Vitamin D | Study of Pembrolizumab, Radiation and Immune Modulatory Cocktail in Cervical/Uterine Cancer (PRIMMO) | Completed | BEL | 0 |
NCT03212404 | Phase I | Cosibelimab | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | Recruiting | POL | NZL | FRA | ESP | AUS | 4 |
NCT03241745 | Phase II | Nivolumab | A Study of Nivolumab in Selected Uterine Cancer Patients | Completed | USA | 0 |
NCT03319628 | Phase I | XMT-1536 | First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b | Active, not recruiting | USA | 0 |
NCT03367741 | Phase II | Cabozantinib + Nivolumab Nivolumab | Cabozantinib and Nivolumab in Treating Patients With Advanced, Recurrent or Metastatic Endometrial Cancer | Active, not recruiting | USA | CAN | 0 |
NCT03476798 | Phase II | Bevacizumab + Rucaparib | Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium | Completed | USA | 0 |
NCT03517449 | Phase III | Lenvatinib + Pembrolizumab Paclitaxel Doxorubicin | Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775]) | Active, not recruiting | USA | TUR | POL | NZL | ITA | ISR | IRL | GBR | FRA | ESP | DEU | CAN | BRA | AUS | ARG | 6 |
NCT03517488 | Phase I | XmAb20717 | A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) | Completed | USA | 0 |
NCT03526432 | Phase II | Atezolizumab + Bevacizumab | Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer | Active, not recruiting | USA | 0 |
NCT03603184 | Phase III | Atezolizumab + Carboplatin + Paclitaxel Carboplatin + Paclitaxel | Atezolizumab Trial in Endometrial Cancer - AtTEnd (AtTEnd) | Active, not recruiting | NZL | ITA | GBR | ESP | DEU | CHE | AUT | AUS | 3 |
NCT03660826 | Phase II | Olaparib Cediranib + Olaparib | Olaparib and Cediranib Maleate in Treating Patients With Recurrent, Refractory, or Metastatic Endometrial Cancer | Active, not recruiting | USA | CAN | 0 |
NCT03752398 | Phase I | Izuralimab | A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3) | Completed | USA | 0 |
NCT03836157 | Phase II | Bevacizumab + Mirvetuximab Soravtansine | Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer | Withdrawn | USA | 0 |
NCT03849469 | Phase I | Pembrolizumab + XmAb22841 XmAb22841 | A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4) | Completed | USA | 0 |
NCT03884101 | Phase III | Carboplatin + Paclitaxel Lenvatinib + Pembrolizumab | Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) | Active, not recruiting | USA | TUR | POL | ITA | ISR | IRL | GBR | ESP | DEU | CAN | BRA | BEL | AUT | AUS | ARG | 7 |
NCT03909152 | Phase II | Onapristone Anastrozole + Onapristone | A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone | Completed | USA | 0 |
NCT03914612 | Phase III | Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Paclitaxel | Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer | Active, not recruiting | USA | CAN | 3 |
NCT03917381 | Phase Ib/II | GEN1046 | GEN1046 Safety Trial in Patients With Malignant Solid Tumors | Active, not recruiting | USA | TUR | POL | ITA | ISR | HUN | ESP | CZE | 2 |
NCT03926936 | Phase II | Fulvestrant | FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study (FUCHSia) | Completed | NLD | BEL | 0 |
NCT03932409 | Phase I | Pembrolizumab | Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer (FIERCE) | Recruiting | USA | 0 |
NCT03955978 | Phase I | Dostarlimab-gxly | TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer | Active, not recruiting | USA | 0 |
NCT04014530 | Phase Ib/II | Pembrolizumab + PTC124 | Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study (ATAPEMBRO) | Recruiting | NLD | 0 |
NCT04065269 | Phase II | Ceralasertib + Olaparib Ceralasertib | ATr Inhibitor in Combination With Olaparib in Gynaecological Cancers With ARId1A Loss or no Loss (ATARI) | Recruiting | GBR | CAN | 0 |
NCT04106414 | Phase II | Nivolumab Linrodostat + Nivolumab | Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment | Active, not recruiting | USA | 0 |
NCT04205630 | Phase II | Trastuzumab Duocarmazine | SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma | Completed | USA | POL | 5 |
NCT04235101 | Phase I | Niraparib + Trastuzumab Duocarmazine | Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors | Completed | NLD | GBR | BEL | 0 |
NCT04251416 | Phase II | Sacituzumab govitecan-hziy | A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma | Recruiting | USA | 0 |
NCT04269200 | Phase III | Durvalumab Durvalumab + Olaparib Carboplatin + Durvalumab + Paclitaxel Carboplatin + Durvalumab + Olaparib + Paclitaxel Carboplatin + Paclitaxel | Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer (DUO-E) | Active, not recruiting | USA | POL | LTU | ISR | HUN | GRC | EST | ESP | DEU | CAN | BRA | BEL | AUS | 9 |
NCT04282018 | Phase Ib/II | BGB-10188 + Zanubrutinib BGB-10188 + Tislelizumab BGB-10188 | Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab | Completed | AUS | 1 |
NCT04450901 | Phase I | YBL-006 | Dose Escalation/Dose Expansion Study of YBL-006 in Patients With Advanced Solid Tumors | Active, not recruiting | AUS | 2 |
NCT04469764 | Phase II | Abemaciclib + Anastrozole Abemaciclib + Letrozole Abemaciclib | Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer | Recruiting | USA | 0 |
NCT04486352 | Phase Ib/II | Atezolizumab + Talazoparib Atezolizumab + Ipatasertib Atezolizumab + Bevacizumab | A Study of Targeted Agents With Atezolizumab for Patients With Recurrent or Persistent Endometrial Cancer (EndoMAP) | Recruiting | USA | 0 |
NCT04513665 | Phase II | ZW25 | ZW25 in Women With Endometrial Cancers | Completed | USA | 0 |
NCT04634877 | Phase III | Carboplatin + Paclitaxel Cisplatin + Paclitaxel Carboplatin + Docetaxel Cisplatin + Paclitaxel + Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Cisplatin + Docetaxel + Pembrolizumab Cisplatin + Docetaxel Carboplatin + Docetaxel + Pembrolizumab | Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053) | Active, not recruiting | USA | TUR | SWE | POL | NOR | ITA | ISR | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BEL | AUT | ARG | 9 |
NCT04652076 | Phase Ib/II | Carboplatin + NP137 + Paclitaxel Trevatide + Pembrolizumab NP137 + Pembrolizumab Carboplatin + NP137 + Paclitaxel Carboplatin + Paclitaxel | GYNecological Cancers Treated With NETrin mAbs in Combination With Chemotherapy and /or Pembrolizumab (GYNET) | Active, not recruiting | FRA | 0 |
NCT04678908 | Phase I | HB0025 | A Study of Injection HB0025 in Patients With Advanced Solid Tumors | Unknown status | USA | 1 |
NCT04719273 | Phase II | Anastrozole + Onapristone | Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer | Active, not recruiting | USA | 0 |
NCT04795661 | Phase II | Pembrolizumab | Immunotherapy in MSI/dMMR Tumors in Perioperative Setting. (IMHOTEP) | Active, not recruiting | FRA | 0 |
NCT04906382 | Phase I | Carboplatin + Paclitaxel + Tislelizumab | Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer | Terminated | USA | 0 |
NCT05032040 | Phase II | XmAb20717 | A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies | Recruiting | USA | 0 |
NCT05036681 | Phase II | Futibatinib + Pembrolizumab | A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma | Recruiting | USA | 0 |
NCT05043714 | Phase I | NG-641 + Nivolumab | Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours (NEBULA) | Active, not recruiting | USA | GBR | 0 |
NCT05069935 | Phase I | Atezolizumab + FT538 Cetuximab + FT538 FT538 + Trastuzumab FT538 + Pembrolizumab FT538 + Nivolumab Avelumab + FT538 Cyclophosphamide + Fludarabine | FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors | Terminated | USA | 0 |
NCT05086692 | Phase Ib/II | MDNA11 + Pembrolizumab | A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1) | Recruiting | USA | CAN | AUS | 1 |
NCT05143970 | Phase I | IPH5301 IPH5301 + Paclitaxel + Trastuzumab | A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors (CHANCES) | Recruiting | FRA | 0 |
NCT05154487 | Phase II | Alpelisib + Fulvestrant | A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer | Recruiting | USA | 0 |
NCT05156268 | Phase II | Olaparib + Pembrolizumab | A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma | Active, not recruiting | USA | 0 |
NCT05173987 | Phase III | Cisplatin + Docetaxel Carboplatin + Docetaxel Carboplatin + Paclitaxel Cisplatin + Paclitaxel Pembrolizumab | Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) | Active, not recruiting | USA | TUR | SWE | POL | NZL | NOR | NLD | ITA | ISR | IRL | HUN | GBR | FIN | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUS | 6 |
NCT05194072 | Phase I | SGN-B7H4V | A Study of SGN-B7H4V in Advanced Solid Tumors | Recruiting | USA | ITA | GBR | ESP | DEU | CAN | 0 |
NCT05255653 | Phase II | Olaparib Medroxyprogesterone Carboplatin Megestrol acetate Paclitaxel Cisplatin Durvalumab | Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) | Recruiting | NLD | GBR | FRA | CAN | 0 |
NCT05269381 | Phase I | Cyclophosphamide + Neoantigen peptide vaccine + Pembrolizumab + Sargramostim | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (PNeoVCA) | Recruiting | USA | 0 |
NCT05300048 | Phase I | Serabelisib Nab-paclitaxel + Serabelisib | Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations | Active, not recruiting | USA | 0 |
NCT05542407 | Phase I | Atezolizumab + ONC201 | ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer | Recruiting | USA | 0 |
NCT05564377 | Phase II | Selumetinib Binimetinib + Fulvestrant Binimetinib + Palbociclib Nilotinib + Paclitaxel Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin Panitumumab + Sotorasib Binimetinib Fulvestrant Olaparib Olaparib + Selumetinib Alpelisib + Olaparib Neratinib Neratinib + Palbociclib Fluorouracil + Leucovorin + Oxaliplatin Ipatasertib + Paclitaxel | Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | Recruiting | USA | 1 |
NCT05603910 | Phase I | Lenvatinib + Pembrolizumab | Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma | Recruiting | USA | 0 |
NCT05714553 | Phase Ib/II | Docetaxel + Leucovorin + NUC-3373 Leucovorin + NUC-3373 + Pembrolizumab | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | Recruiting | GBR | 0 |
NCT05795595 | Phase Ib/II | CTX131 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors | Recruiting | USA | 0 |
NCT05904496 | Phase I | BGB-30813 BGB-30813 + Tislelizumab | A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | ESP | AUS | 0 |
NCT05949424 | FDA approved | Lenvatinib Olaparib Pazopanib Palbociclib Sunitinib | OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults (OPTI-DOSE) | Not yet recruiting | NLD | 0 |
NCT05958199 | Phase I | NPX267 | Treatment With NPX267 for Subjects With Solid Tumors Known to Express HHLA-2 | Recruiting | USA | 0 |
NCT06046274 | Phase II | GEN1046 + Pembrolizumab | GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer | Withdrawn | USA | ITA | ESP | DNK | BEL | 1 |
NCT06132958 | Phase III | Paclitaxel Doxorubicin SKB264 | MK-2870 in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) | Recruiting | USA | SWE | POL | NOR | NLD | ITA | ISR | IRL | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 8 |
NCT06172478 | Phase II | Patritumab deruxtecan | A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | 2 |
NCT06444815 | Phase I | VET3-TGI Pembrolizumab + VET3-TGI | A Study of VET3-TGI in Patients With Solid Tumors (STEALTH-001) | Recruiting | USA | 0 |
NCT06481592 | Phase II | Aldesleukin + Lifileucel Cyclophosphamide + Fludarabine | A Study of Lifileucel (tumor-infiltrating Lymphocytes) in Adults with Advanced Endometrial Cancer. | Recruiting | USA | 0 |
NCT06486441 | Phase III | Doxorubicin Paclitaxel Sacituzumab govitecan-hziy | Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26) (ASCENT-GYN-01) | Recruiting | USA | 0 |
NCT06660654 | Phase II | Raludotatug deruxtecan | A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01) | Not yet recruiting | USA | 0 |